Chicago – August 27, 2025 — The South Florida Clinical Research Institute (SFCRI) is proud to announce that our team has been recognized for outstanding performance in an Eli Lilly clinical trial, part of the GPIJ obesity and diabetes research program. This recognition highlights SFCRI’s leadership in clinical trial retention, a crucial factor in producing high-quality, reliable study outcomes.

Our dedicated staff received an award for achieving more than 95% retention among low-risk participants, a critical metric in ensuring reliable, high-quality trial results. In fact, less than 10% of participants left the study, underscoring the commitment of both our team and our patients to advancing science and improving care.

About the GPIJ Obesity and Diabetes Program

The Global Patient Innovation (GPIJ) program focuses on developing new treatments for obesity-related conditions and type 2 diabetes, two of the most pressing health challenges worldwide. With obesity rates climbing and diabetes affecting millions, the program aims to:

  • Evaluate innovative medications that improve weight management and blood sugar control.
  • Improve long-term cardiometabolic outcomes for patients at risk.
  • Provide data that helps shape future standards of care in obesity and diabetes treatment.

By maintaining excellent patient engagement and trial retention, SFCRI contributes to building the robust, reliable evidence needed to advance these promising therapies.

SFCRI’s Commitment

This clinical trial retention recognition highlights SFCRI’s mission-driven approach:

  • Advancing Science & Care — conducting innovative, ethical, and patient-centered clinical research.
  • Strong Patient Retention — fostering trust and delivering reliable data through compassionate care.
  • Experienced Team — with over 35 years of combined expertise, fluent in both English and Spanish, our staff ensures patients feel supported throughout their trial journey.

“We are honored to contribute to groundbreaking obesity and diabetes research alongside Eli Lilly,” said the SFCRI leadership team. “This award reflects not just our scientific rigor, but also our commitment to patient well-being.”

As one of Florida’s leading clinical research centers, SFCRI continues to partner with sponsors and investigators to bring new treatment opportunities to patients while delivering high-quality, ethical results.

Interested in joining groundbreaking research that advances science and patient care? Become part of an SFCRI clinical trial today. Learn More & Enroll.